Zobrazeno 1 - 10
of 4 471
pro vyhledávání: '"mesalazine"'
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation of the colon. Tanshinone IIA, a compound derived from traditional Chinese medicine, has demonstrated anti-inflammatory propert
Externí odkaz:
https://doaj.org/article/0d5d73b4bc65431e84c2a493b22e9e1f
Autor:
Stephan R. Künzel, Erik Klapproth, Nick Zimmermann, Susanne Kämmerer, Mario Schubert, Karolina Künzel, Maximilian Hoffmann, Stephan Drukewitz, Anne Vehlow, Jiri Eitler, Marieke Arriens, Jessica Thiel, Romy Kronstein-Wiedemann, Maximiliane Tietze, Stefan Beissert, Bertold Renner, Ali El-Armouche, Claudia Günther
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract Radiation-induced morphea (RIM) is a rare complication of radiotherapy presenting as inflammatory fibrosis, most commonly reported in breast cancer patients. As underlying disease mechanisms are not well understood, targeted therapies are la
Externí odkaz:
https://doaj.org/article/ca14d9c2e1744a85acf698b849bb68f5
Publikováno v:
Frontiers in Microbiology, Vol 15 (2024)
The treatment of inflammatory bowel disease (IBD) remains challenging and significantly impacts both patients and their families. This study evaluated the role of Bifidobacterium animalis subsp. lacti XLTG11 (XLTG11) in combination with mesalazine (5
Externí odkaz:
https://doaj.org/article/396fbe7b28764213bf2b8e1be74c03f2
Autor:
Shabnam Bahrami, Nahid Babaei, Hadi Esmaeili Gouvarchin Ghaleh, Jaleh Mohajeri Borazjani, Mahdieh Farzanehpour
Publikováno v:
Frontiers in Molecular Biosciences, Vol 11 (2024)
IntroductionUlcerative colitis (UC), a common gastrointestinal disorder in affluent nations, involves chronic intestinal mucosal inflammation. This research investigated the effects of combined probiotic treatment of Lactobacillus casei (L. casei) an
Externí odkaz:
https://doaj.org/article/e7f62e16712f4344b772d6a259d6751a
Publikováno v:
Biomedicines, Vol 12, Iss 10, p 2241 (2024)
Objective: We took advantage of a single-center cross-sectional study to investigate the effect of different drugs on intestinal microbiota and function in Crohn’s disease. Methods: We studied the difference in fecal microbiota of Crohn’s disease
Externí odkaz:
https://doaj.org/article/1383018ef6b14c559af9b87172c2a3fa
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Purpose: Current pharmacological treatments for Ulcerative Colitis (UC) have limitations. Therefore, it is important to elucidate any available alternative or complementary treatment, and Chinese herbal medicine shows the potential for such treatment
Externí odkaz:
https://doaj.org/article/ccec2a33e7514ef6940c6c06685d30f0
Publikováno v:
Clinical Case Reports, Vol 12, Iss 4, Pp n/a-n/a (2024)
Key Clinical Message This case report describes the clinical course of a 64‐year‐old male with intermittent abdominal pain attributed to recurrent ulcers at the appendiceal orifice. Initial investigations in November 2019 revealed chronic gastrit
Externí odkaz:
https://doaj.org/article/baaf2a8a1c064efba6bff9a30e00bfd6
Autor:
Abdussamed Mohammed Ali Saeed, Intisar Adil Shihab Al-Hammoodi, Mohammed Salim Al-Enizzi, Suhair Mahfoodh Salih
Publikováno v:
Pakistan Journal of Analytical & Environmental Chemistry, Vol 24, Iss 2, Pp 135-144 (2023)
A novel green, straightforward, and precise spectrophotometric method for determination of mesalazine drug has been developed. This method relies on an oxidative coupling reaction between mesalazine and the environmentally friendly phenoxazine reagen
Externí odkaz:
https://doaj.org/article/d50748a6e7a84b3990df48c932e371da
Autor:
M. Valvano, A. Vinci, N. Cesaro, S. Frassino, F. Ingravalle, M. Ameli, A. Viscido, S. Necozione, G. Latella
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background The introduction of biological drugs has led to great expectations and growing optimism in the possibility that this new therapeutic strategy could favourably change the natural history of Inflammatory Bowel Disease (IBD) and, in
Externí odkaz:
https://doaj.org/article/cea49d718ebc4c328fa1ef0d9e7daa2d
Autor:
Elina Armani, Parisa Jafari, Salar Hemmati, Elaheh Rahimpour, Mohammad Barzegar-Jalali, Abolghasem Jouyban
Publikováno v:
BMC Chemistry, Vol 17, Iss 1, Pp 1-12 (2023)
Abstract Mesalazine (5-ASA) is a medication utilized to treat inflammatory bowel diseases involving ulcerative colitis and Crohn’s disease. Mesalazine has fewer side effects but the low solubility and bioavailability of it is responsible for its de
Externí odkaz:
https://doaj.org/article/a22045a3c1144430977a3c3211aeea93